Source comparison
Capsule Side Effects vs Injectable Side Effects
The administration route changes which side effects dominate. This comparison table covers the most reported effects across both forms. Nausea Common (20-30%) Uncommon (<10%) Diarrhea Common in first week Rare Bloating Headache Uncommon (~5-10%) More common (~
This comparison does not assign a generated winner or score.
- The administration route changes which side effects dominate. This comparison table covers the most reported effects across both forms.
- Nausea
- Common (20-30%)
- Uncommon (<10%)
- Diarrhea
- Common in first week
- Rare
- Bloating
- Headache
- Uncommon (~5-10%)
- More common (~15-20%)
- Injection-site pain
- Not applicable
- Common (~25%)
- Injection-site redness
- Common (~15-20%)
- Dizziness
- Uncommon (~10%)
- Fatigue
- Appetite changes
- Occasional
- Oral users trade injection-site discomfort for GI symptoms. Injectable users trade GI comfort for site reactions and more frequent headaches.
- The pharmacokinetic data explains why. He et al. (2022) showed that oral BPC-157 in rats produced peak plasma concentrations 60-90 minutes after administration, compared to 15-30 minutes for subcutaneous injection (He et al., Front Pharmacol, 2022). The slower rise with oral dosing reduces the acute vasodilatory spike that causes headaches, but the prolonged GI transit time increases local mucosal exposure.
- For capsule-specific headache information, see does BPC-157 cause headaches. For GI-specific details, see can BPC-157 cause diarrhea.